MedTrace Logo

Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

NCT02981719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2021-01-22

No results posted yet for this study

Summary

The aim of this study was to compare the therapeutic efficacy between simultaneous gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer (LAPC)

Conditions

Interventions

PROCEDURE

simultaneous gemcitabine and irreversible electroporation

gemcitabine intravenous infusion prior to irreversible electroporation treatment

PROCEDURE

irreversible electroporation

percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Niu, PHD · Fuda Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2018-10-01
Completion
2020-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02981719 on ClinicalTrials.gov